|HOME | ABOUT US | PIPELINE | R & D | PUBLICATIONS | PARTNERING | INVESTORS | CAREERS | CONTACT|
- Alzheimer’s Disease
Epilepsy is a medical condition that affects millions of individuals in the US and throughout the world. This disease produces seizures affecting a variety of mental and physical functions. It’s also called a seizure disorder. When a person has two or more unprovoked seizures, they are considered to have epilepsy.
Epilepsy represents a large and growing market opportunity. According to the Epilepsy Foundation, there are an estimated 2.5 million patients in the United States, with approximately 180,000 new cases diagnosed in the United States each year.
A range of antiepileptic drugs have been marketed worldwide in recent decades, however there is still a great unmet need for drugs that produce better results with fewer side effects. Current drugs treat symptoms rather than halting the disease’s progression or preventing it outright. The world market for epilepsy therapies was US$10.4 billion in 2004, and is projected to grow to US$13.2 billion by 2010 and US$ 15.3 billion by 2015.
Anavex is developing novel compounds, aiming to develop a genuine disease-modifying treatment for epilepsy.
ANAVEX 2-73 and ANAVEX 19-144
Mode of action: ANAVEX 2-73 and its metabolite present mixed pharmacological activity involving muscarinic, sodium channel, NMDA and sigma-1 components showing prominent anti-amnesic, anti-convulsive and anti-depressing potential.
Results to date: In epilepsy animal models, both compounds (ANAVEX 2-73 and its metabolite) exhibited very efficient anti-convulsive action, inhibition of tonic crises in maximal electroshock seizures (MES) and pentetetrazole (PTZ) models of generalized convulsions.
|© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.|